Tue, Jan 27, 2015, 6:59 AM EST - U.S. Markets open in 2 hrs 31 mins

Recent

% | $
Quotes you view appear here for quick access.

Aethlon Medical, Inc. Message Board

robert.vince 96 posts  |  Last Activity: Jan 23, 2015 7:55 AM Member since: Aug 30, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • CytoSorbents Corporation a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced the receipt of $385,642, net of transaction costs, in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority (NJEDA). Funds will be used to help expand manufacturing of CytoSorb® and support sales of CytoSorb® internationally.
    The New Jersey Technology Business Tax Certificate Transfer Program enables approved Technology and Biotechnology Businesses with Net Operating Losses to sell their Unused Net Operating Loss Carryover (NOL) and Unused Research and Development Tax Credits (R&D Tax Credits) for at least 80% of the value of the tax benefits to a profitable corporate taxpayer in the State of New Jersey that is not an Affiliated Business. This allows Technology and Biotechnology Businesses with Net Operating Losses to turn their tax losses and credits into cash to buy equipment or facilities, or for other Allowable Expenditures. The New Jersey Economic Development Authority (NJEDA) determines eligibility, and the New Jersey Division of Taxation determines the value of the tax benefits (NOL and R&D Tax Credits).

    Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, "As a high growth, international therapeutics company with distribution of CytoSorb® in 28 countries around the world, and continued expansion of our manufacturing, R&D and administrative facility in New Jersey, we thank the continued support of the NJEDA. Over the past 6 years, we have obtained nearly $7.5 million in non-dilutive government grants, contracts and other funding, an important part of our overall financing strategy."

    Sentiment: Strong Buy

  • robert.vince robert.vince Jan 22, 2015 12:29 PM Flag

    Only cause nobody knows about it yet. You're in on the bottom floor and they either go bankrupt or we get rich. If you go to their site, they have a customer count listed at the top of the page, after months of losing customers, they're finally firing on all cylinders, adding new users every day. They got a million dollar line of credit to keep items in stock, which is why they were losing customers. I bought at $3 a share, then bought lots more when it hit a buck, but I don't think there are many shares to go around right now, hence the low trading volume. They're trying to uplist this year, thats when it takes off imho. Good luck to you (and me)!

  • Green PolkaDot Box Incorporated (GPDB) reports today that sales in all categories through the middle of January are sharply higher than the comparable 2014 period coming in at $210,000. The blended gross margin on sales exceeds 50%. Combined sales, as of January 15th, are more than 19% above total December sales, suggesting GPDB will likely earn profit on operations for the first time in its history.

    "Of course, I'm pleased with the results," says GPDB CEO, Rod Smith. "But we are just getting started. Customer growth is also trending higher. Through mid-January 2015, we added over 950 new customers, meeting our projections. A significant portion of new customer growth is coming through GPDB's Health Merchant program."
    Through Amazon, January sales of Appethyl(R) have exceeded management's expectations and are expected to continue strong. After two weeks of sales on Amazon, Appethyl(R) by Green PolkaDot Box already ranks high in the "Shakes and Powders" sub-category. GPDB is also close to establishing additional channels of sales and distribution.

    Preparations to GPDB's Up Listing

    On a separate business front, the Company is conducting an audit. CEO Rod Smith states: "We are preparing to position GPDB to become fully-reporting and list on a major exchange. We believe 2015 will be our break out year."

    Green PolkaDot Box America's premier online membership club for organic and non-GMO natural foods at wholesale pricing. GPDB is the only major online store that refuses to carry products or ingredients containing GMO. GPDB leverages proprietary technology with its dynamic, interactive website and member relationship management software to provide a unique shopping and membership experience. GPDB plans to grow membership with families looking for natural non-GMO products and organic choices for up to a 60% discount off retail prices.

    Sentiment: Strong Buy

  • robert.vince robert.vince Jan 20, 2015 10:36 AM Flag

    Early Financial Impact Seems Positive

    The initial impact of these initiatives appear to be positive, we believe; earlier this month, the company announced that sales advanced about 65% sequentially in December 2014. This reflected a roughly 31% advance in its core online general goods business, as higher inventory levels enabled order fulfillment, augmented by the early positive response to the Health Merchant program.

    The company also noted that Appethyl sales through Amazon in early January were ahead of expectations. Through January 5, aggregate revenue from Appethyl and the Health Merchant program were north of $65,000, which represents about 37% of total monthly sales in December 2014, according to management, which believes that January monthly revenue could be on-track to beat that of November and December combined.

  • robert.vince robert.vince Jan 16, 2015 11:56 AM Flag

    Early Financial Impact Seems Positive

    The initial impact of these initiatives appear to be positive, we believe; earlier this month, the company announced that sales advanced about 65% sequentially in December 2014. This reflected a roughly 31% advance in its core online general goods business, as higher inventory levels enabled order fulfillment, augmented by the early positive response to the Health Merchant program.

    The company also noted that Appethyl sales through Amazon in early January were ahead of expectations. Through January 5, aggregate revenue from Appethyl and the Health Merchant program were north of $65,000, which represents about 37% of total monthly sales in December 2014, according to management, which believes that January monthly revenue could be on-track to beat that of November and December combined.

    Sentiment: Strong Buy

  • robert.vince robert.vince Jan 16, 2015 11:39 AM Flag

    Statistics indicate that ad recall of a cinema ad beats that of a TV ad. For example, according to the Cinema Advertising Council (CAC), a study released by the NYU Stern Center for Measurable Marketing found that cinema can be as effective or more than TV for “generating significant sales volume per ad dollar spent.“ There is also no disruptive ad skipping technology with cinema ads; they are viewed live.

    Given the rising incidence of obesity, Appethyl could have significant commercial potential, in our opinion.According to the CDC, 34.9% of American adults are obese. Obesity rates in adults and children have more than doubled since the 1970’s, according to the National Center for Health Statistics. Health conditions that are related to obesity include heart disease, stroke, type 2 diabetes and certain cancers. Moreover, obese people average $1,429 higher per annum spending on medical care than people of average weight. In addition to Appethyl, management has also indicated that it is in discussions for exclusive distribution of other innovative natural products.

    New Credit Line

    In October 2014, Green PolkaDot Box announced that one of its key investors had agreed to provide GPDB access to a $1 million credit line, which management earmarked to triple inventory levels in anticipation of growing demand. Reflecting the initiatives noted above, as well as the company’s distribution agreement with Amazon, management is optimistic about upcoming order flow and intends to have sufficient inventory to fulfill orders.

    Management noted that it has been difficult in recent months for GPDB to sustain full inventory levels, which in turn has constrained sales and customer retention. The company believes that access to this credit facility, in conjunction with the cash flow from the Health Merchant program, will help alleviate inventory pressure

    Sentiment: Strong Buy

  • From Zacks
    Several recent initiatives by Green PolkaDot Box (GPDB), a membership club that offers organic and natural products to its members at attractive prices, have shown early momentum, we believe. These include the company’s recently introduced Health Merchant program, marketing for appetite suppressant Appethyl and the positive impact of a new credit line. We believe the market opportunity for GPDB is significant, as consumer interest in organic products is growing rapidly. In our view, the company continues to add new ways to tap into this high growth market.

    Health Merchant Program

    In November 2014, the company unveiled a new Health Merchant program that enables health professionals and others to launch a turnkey, self-branded online health products store, with Green PolkaDot Box providing back office and logistics. The company’s target market for this program includes doctors with disease prevention practices, nutritionists, chiropractors, gym operators, personal fitness trainers and pharmacists, among others.

    For $300 up to $1,995, depending on which package the health practitioner selects, Health Merchants get an online health and wellness store that offers a broad range of natural products at competitive prices. For a $100 monthly service fee, GPDB handles the logistics, from product acquisition, inventory storage, website hosting and maintenance, liability insurance, online order processing to shipping and customer service.

    Health Merchants also get access to a media kit including informational videos that GPDB will update frequently. Green PolkaDot Box also offers weekly specials, supported with electronic marketing. The company believes these promotions give GPDB a higher than average conversion rate of first time website visitors into repeat customers.

    Sentiment: Strong Buy

  • Arch Therapeutics, Inc. (OTCQB: ARTH) , developer of the AC5 Surgical Hemostatic Device™, obtained positive results when AC5™ was subjected to a standardized medical device test for irritation potential. The irritation test in animals is a major component of the International Organization for Standardization's (ISO) required panel of biocompatibility testing necessary for medical devices prior to use in humans. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care.

    In this standard three-day in vivo rabbit model study, AC5 tested in relevant amounts was well tolerated, gave a zero (0) irritation score and was classified as a negligible irritant using a standardized scoring system. A device in this study can be classified and scored as negligible (0.0-0.4), slight (0.5-1.9), moderate (2.0-4.9) or severe (5.0-8.0). Results from this biocompatibility safety study indicate that AC5's peptide structure and mechanism of action, which is based on the formation of a local physical-mechanical barrier at the wound site, does not promote application site erythema or edema, which are indices of irritation. This study represents further data supporting the absence of toxicity for AC5, and represents an important step in demonstrating biocompatibility of AC5.

    Arch Therapeutics President and CEO Terrence Norchi, MD, stated, "These promising results underscore our positive expectations for AC5. We look forward to additional studies with AC5 that indicate its potential value in terms of safety, efficacy and user-friendliness."

  • Stellar Biotechnologies, Inc announced today that the Company's management team will present at the 7th Annual Biotech Showcase 2015 conference, being held at the Parc 55 Wyndham Hotel in San Francisco, CA, on Tuesday, January 13 at 2:30 p.m. PST.

    Stellar Biotechnologies' Presentation Details
    Date: Tuesday, January 13, 2015
    Time: 2:30 p.m. PST
    Location: Parc 55 Wyndham Hotel, 55 Cyril Magnin Street, San Francisco, CA
    Room & Track: C-Mission II (4th Floor)

    About Biotech Showcase 2015
    The Biotech Showcase 2015 conference takes place January 12-14, 2015, at the Parc 55 Wyndham Hotel located in Union Square, San Francisco, California. Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,500 attendees.

  • Aethlon Medical, Inc. (AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that James A. Joyce, Chief Executive Officer, will present at the Biotech Showcase 2015 Conference on Wednesday, January 14, 2015. Details of Aethlon Medical's presentation are as follows:

    Event:
    Biotech Showcase 2015
    Date:
    Wednesday, January 14, 2015
    Time:
    4:00 p.m. Pacific Time / 7:00 p.m. Eastern Time
    Location:
    Parc 55 Wyndham Union Square, San Francisco, CA
    A live audio webcast of the presentation will be available on the Company's website in the Investor Relations section on the Events and Presentations . The webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.

    About Biotech Showcase 2015
    The Biotech Showcase 2015 conference takes place January 12-14, 2015, at the Parc 55 Wyndham Hotel located in Union Square, San Francisco, California. Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,500 attendees.

  • Reply to

    Vista Partners Jan Newsletter and CTSO

    by robert.vince Jan 7, 2015 9:53 AM
    robert.vince robert.vince Jan 7, 2015 11:26 AM Flag

    The Company continues to advance their business through the ongoing commercial ramp of CytoSorb®
    in 28 countries worldwide and a planned pivotal cardiac surgery trial in the U.S. On Dec 30th, the
    Company announced, it has submitted an Investigational Device Exemption (IDE) application to the U.S.
    Food and Drug Administration (FDA) to conduct its proposed clinical trial using CytoSorb® intraoperatively
    in patients undergoing complex cardiac surgery requiring the use of a heart-lung machine.
    The goal of CytoSorb® treatment is to reduce inflammatory mediators and proteins such as cytokines
    and plasma free hemoglobin generated during surgery that can lead to serious post-operative
    complications.
    Mr. Vincent Capponi, Chief Operating Officer of CytoSorbents stated, "The submission of this IDE
    application represents a major milestone for the Company, initiating the clinical trial process needed to
    seek approval of CytoSorb® in the United States. With approximately half a million cardiac surgery
    procedures such as valve replacement and coronary artery bypass graft surgeries each year in the U.S.
    alone, and another one million in the rest of the world annually, we believe this represents a significant
    potential commercial opportunity for the Company."Vista Partners LLC - January 2015
    7
    CytoSorb®, and the other products in the Company’s pipeline, may have significant upside considering
    the massive markets they seek to address. CTSO has received validation of their technologies potential
    from many large organizations in the form of research grants and other agreements including: BioCon,
    DARPA, U.S. Army, U.S. Air Force, NIH/NHLBI, scientific advisors & analysts. The Company enjoys a
    unique, high margin product and pipeline with little to no current competition and is currently selling
    their flagship product CytoSorb® in Europe and the Middle East.

  • CytoSorbents Corporation (“CTSO” or the “Company”), which has seen its share price more than triple
    since we initiated coverage in January 2014, is based in Monmouth Junction, NJ, and is a publicly
    traded, critical care immunotherapy focused company using blood purification to treat life-threatening
    illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can
    actively remove toxic substances from blood and other bodily fluids by pore capture and surface
    adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove
    substances as small as drugs, to substances as large as antibodies. The Company is on the “ground floor”
    of commercialization and positioned to potentially create significant value with their product, CytoSorb®,
    which has the potential to revolutionize critical care medicine; save lives, and reduce healthcare costs.
    CytoSorb is as an extracorporeal cytokine adsorber, and can be used with standard hemodialysis
    machines in any situation where cytokines are elevated. This includes a diverse range of conditions
    where cytokines are driving a potentially dangerous inflammatory response, including acute critical
    illnesses such as sepsis and infection, burn injury, trauma, acute respiratory distress syndrome, severe
    acute pancreatitis, liver failure, influenza, and complications of cardiac surgery, as well as in other more
    chronic diseases such as cancer, cancer cachexia, autoimmune diseases, and others.
    CytoSorbents began trading on the Nasdaq on Dec. 23, 2014. This up-listing to NASDAQ is a significant
    corporate milestone for CytoSorbents, and is the latest in a series of important accomplishments for the
    Company.

  • robert.vince robert.vince Jan 7, 2015 9:08 AM Flag

    About OneMedForum 2015

    OneMedForum 2015 is a leading annual healthcare-focused investor conference bringing together more than 100 presenting growth companies and over 1,300 investors. By connecting companies and investors, the forum helps advance the firms shaping the future of health and medicine. This year, OneMedForum plans to launch OneMedMarket, a marketplace for builders and financiers of healthcare growth companies. Public companies will also be featured on OneMedTV through live streaming of their company presentations as well as the distribution of interviews with CEOs.

    About SCCM

    The Society of Critical Care Medicine (SCCM) is a non-profit organization that represents nearly 16,000 highly trained professionals in more than 100 countries whose collective goal is to secure the highest quality care for all critically ill and injured patients. The SCCM envisions a day when all such patients are cared for by a dedicated team of physicians, nurses, and other medical professionals specifically trained in critical care. The organization publishes Critical Care Medicine, the premier peer-reviewed, scientific journal in critical care, as well as Pediatric Critical Care Medicine, the first scientific, peer-reviewed journal to focus exclusively on pediatric and neonatal critical care.

  • CytoSorbents Corporation (NASDAQ CM: CTSO), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced that Dr. Phillip Chan, Chief Executive Officer, will present at the OneMedForum 2015 conference on Monday, January 12, 2015 at 2:00PM PST in the Marriott Marquis Hotel in San Francisco, California. A copy of the presentation will be posted to the Company's website following the conference. The conference is run concurrently with, but independently from, the 33rd Annual JP Morgan Healthcare Conference in San Francisco (January 12-15, 2015), one of the largest and most influential international healthcare conferences. During the conference, Dr. Chan will be joined by Kathleen Bloch, Chief Financial Officer, and Chris Cramer, Vice President of Business Development to meet with many analysts and investors.
    In addition, CytoSorbents will exhibit at the upcoming Society of Critical Care Medicine (SCCM) 44th Critical Care Congress from January 17-19, 2015 at the Phoenix Convention Center in Phoenix, Arizona. More than 4,000 critical care clinicians from the U.S. and abroad are expected to attend. The Company will be showcasing its CytoSorb® blood purification therapy and discussing with U.S.-based clinicians the various treatment successes to date in critical care medicine, such as in sepsis, influenza, burn injury, trauma, acute lung injury, pancreatitis, liver failure, treatment of post-operative inflammation, and others. CytoSorb® is approved in the European Union and being marketed in 28 countries around the world, but is not yet approved in the United States.

  • Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, obtained positive results from preclinical tests in which AC5™ was subjected to a battery of high-throughput in vitro safety assessments for biological interactions in standardized testing panels of receptors on the surface of cells and protein kinase enzymes inside cells. These receptors and enzymes represent important biochemical "switches," and interactions with them could indicate biological activity with the potential for toxicity. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care.

    In this in vitro study panel, AC5 tested in relevant amounts had no interactions with the examined 71 individual cell receptors or 211 separate cell kinase enzymes. These outcomes support AC5 as a non-toxic product to biochemical targets. Results from these safety interaction studies indicate that AC5's mechanism of action, which is the formation of a local physical-mechanical barrier, does not rely on AC5's interaction with known human receptors or enzymes to inhibit bleeding and leaking.

    Arch Therapeutics President and CEO Terrence Norchi, MD, stated, "These differentiating results provide additional safety experience with AC5. The data highlights that there is no evidence of unintended interactions with the nearly 300 tested targets in the body, and it underscores the straightforward mechanism of action. We believe that AC5 has the potential to be a standout in terms of safety, efficacy and user friendliness."

    Sentiment: Strong Buy

  • Green PolkaDot Box Incorporated (GPDB) "GPDB" America's premier online membership club for wholesale priced organic and non-GMO natural foods announced today that sales in all categories were up in December 2014 over November 2014 by approximately 65%. Growth in the Company's Health Merchant program remains strong; and Appethyl(R) sales started coming in strong at December's month's end. Sales of general goods in December were up by approximately 31% due to an increase in membership and reaching full inventory.

    Early January sales of Appethyl(R), the new all natural appetite control product through Amazon exceeded management's expectations. Early sales of Health Merchantships--in anticipation of the national launch to occur later this month--are suggesting that January sales could beat November and December sales, combined.

    Already, in early January between the 1st and 5th combined sales have exceeded $65,000 or about 37% of December total sales. GPDB management is confident that both Appethyl(R) and the Health Merchant program have broad appeal and the marketplace is just beginning to respond.

    "Based on early sales results, we anticipate that customer growth in this first month of the year will increase from the current level of approximately 4,200 to more than 6,000," says GPDB CEO, Rod Smith, "and that we will see corresponding increases in monthly sales in January. The foundation that Greenpolkadotbox laid in 2014 is starting to pay off.

  • robert.vince robert.vince Jan 5, 2015 10:46 AM Flag

    I agree, just throwing it all out there when I see it.

  • Article from Zacks
    Cytosorbents Corporation (CTSO - Analyst Report) is a Medical Products industry stock that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

    These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CTSO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Cytosorbents could be a solid choice for investors.

    Current Quarter Estimates for CTSO

    In the past 30 days, 1 estimate has gone higher for Cytosorbents while no estimate has gone lower in the same time period. The trend has been pretty favorable too, with loss estimates narrowing from a loss of 25 cents a share 30 days ago, to a loss of 18 cents today, a move of 28%.

    Current Year Estimates for CTSO

    Meanwhile, Cytosorbents’s current year figures are also looking quite promising, with 1 estimate moving higher in the past month, compared to no lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 92 cents per share 30 days ago to a loss of 87 cents per share today, move of 5.4%.

    Bottom Line

    The stock has also started to move higher lately, adding 107.6% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future.

  • robert.vince robert.vince Jan 5, 2015 9:57 AM Flag

    The present Ebola outbreak is considered the most severe on record and killed no less than 7,905 lives until now. The most common symptoms displayed by Ebola Virus carriers are fever, strong headaches, muscle distress, diarrhea, stomachache and external bleeding, as indicated by U.S. Centers for Disease Control and Prevention (CDC).

    Ebola is contagious if healthy people come in contact with bodily fluids of the infected including “urine, saliva, sweat, feces, vomit, breast milk, and semen”, as per the CDC. Also, contact with tainted syringes or fruit bats and primates can prompt the spread of the ailment.

    The device is also being tested in India to examine if it can speed up the viral load reduction when combined with a hepatitis C treatment.

  • The U.S. Food and Drug Administration approved clinical testing for an Ebola treatment this week. This new treatment is produced by Aethlon Medical Inc., a San-Diego based company. The treatment, called Aethlon’s Hemopurifier blood filter has been approved for patients infected with Ebola that are inside the United States.
    This is not a drug but a bio-filtration gadget created for a one- time-use treatment to expel infections found within the blood system like the lethal and easily contagious Ebola virus. The medical device particularly focuses on any antiviral medication resistance of the virus. This type of treatment aims to serve as a basic countermeasure to Ebola (and different infections) which can’t be tackled with current medication treatments.

    The endorsement of this Ebola treatment will permit research to be conducted in 10 areas and 20 subjects nationwide. Every selected patient will get a Hemopurifier daily administration. The devices will be used from six to eight hours until the Ebola viral load goes under 1,000 duplicates every blood ml.

    Of course, the objective of the study is to establish a standard practice and assess how to successfully and effectively utilize the item to treat Ebola worldwide.

    According to Aethlon reports, the Hemopurifier treatment was successful when a patient in a Critical Ebola condition received the treatment in Frankfurt University Hospital in Germany. The virus duplicates per mL of blood with the given patient were of 400,000. After being administered a 6.5-hour treatment the Ebola virus duplicates drastically tumbled to 1,000 per mL of blood.

    At the time Aethlon started its treatment, the patient was not conscious and was struggling with multiple organ failure, being on the verge of dying. After the treatment his condition improved significantly. Slowly the patient was completely recovered and was able to return home to his family.

AEMD
0.2715+0.0125(+4.83%)Jan 26 3:48 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.